Kraig Biocraft Labs Files S-1

TL;DR

Kraig Biocraft Labs filed an S-1 on 2/7/25. Check financials for 9/30/24.

AI Summary

Kraig Biocraft Laboratories, Inc. filed an S-1 form on February 7, 2025, detailing its business operations. The company is involved in the production of plastic materials, synthetic resins, and rubber, with its principal executive offices located in Ann Arbor, Michigan. The filing provides financial data for the periods ending September 30, 2024, and December 31, 2023, and 2022.

Why It Matters

This S-1 filing provides investors with crucial financial and operational details about Kraig Biocraft Laboratories, Inc. as it navigates the chemical and materials sector.

Risk Assessment

Risk Level: medium — S-1 filings often indicate a company is seeking to raise capital or undergo significant corporate changes, which inherently carries risk.

Key Numbers

• 2024-09-30 — Reporting Period End Date (Latest interim financial data available in the filing.)
• 2023-12-31 — Fiscal Year End Date (Previous full fiscal year financial data.)

Key Players & Entities

• Kraig Biocraft Laboratories, Inc. (company) — Filer of the S-1 document
• 20250207 (date) — Filing date of the S-1
• Ann Arbor, Michigan (location) — Location of company's business and mailing address
• 2024-09-30 (date) — End of reporting period for financial data
• 2023-12-31 (date) — End of reporting period for financial data
• 2022-12-31 (date) — End of reporting period for financial data

FAQ

Key Financial Figures

• $0.0001 — 7,193 shares of common stock, par value $0.0001 per share ("Common Stock"), of Kraig Bi
• $10,000,000 — rchase from us, at our direction, up to $10,000,000 of Common Stock, subject to terms and c
• $0.0975 — Common Stock as quoted on the OTCQB was $0.0975 per share. Quotes of stock trading pric
• $40 million — which they committed to purchase up to $40 million worth of product. This partnership will

Filing Documents

• forms-1.htm (S-1) — 3821KB
• ex23-1.htm (EX-23.1) — 4KB
• ex107.htm (EX-FILING FEES) — 12KB
• forms-1_002.jpg (GRAPHIC) — 4KB
• forms-1_003.jpg (GRAPHIC) — 4KB
• forms-1_004.jpg (GRAPHIC) — 4KB
• forms-1_005.jpg (GRAPHIC) — 9KB
• forms-1_001.jpg (GRAPHIC) — 8KB
• ex23-1_001.jpg (GRAPHIC) — 30KB
• 0001493152-25-005415.txt ( ) — 14805KB
• kblb-20240930.xsd (EX-101.SCH) — 68KB
• kblb-20240930_cal.xml (EX-101.CAL) — 60KB
• kblb-20240930_def.xml (EX-101.DEF) — 339KB
• kblb-20240930_lab.xml (EX-101.LAB) — 539KB
• kblb-20240930_pre.xml (EX-101.PRE) — 456KB
• forms-1_htm.xml (XML) — 3081KB

BUSINESS

BUSINESS 28 MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 37 DIRECTORS AND EXECUTIVE OFFICERS 48 EXECUTIVE COMPENSATION 51 SECURITY 55 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 56 DETERMINATION OF OFFERING PRICE 57 SELLING SECURITYHOLDERS 57 PLAN OF DISTRUBITION 58 DESCRIPTION OF SECURITIES 60 CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS 66 LEGAL MATTERS 67 EXPERTS 67 WHERE YOU CAN FIND MORE INFORMATION 67 PART II 68 INDEX TO FINANCIAL STATEMENTS F-1 3 About this Prospectus We have not authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus or any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We do not take responsibility for, or provide any assurance as to the reliability of, any other information that others may give you. We will not make an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. We may also provide a prospectus supplement or post-effective amendment to the registration statement to add information to, or update or change information contained in, this prospectus. You should read both this prospectus and any applicable prospectus supplement or post-effective amendment to the registration statement together with the additional information to which we refer you in the sections of this prospectus entitled "Where You Can Find More Information." "Kraig", "Kraig Biocraft" "KBLB", "the Company", "we", "us" and "our" refer to Kraig Biocraft Laboratories, Inc., a Wyoming corporation, unless the context otherwise requires. Industry and Market Data Unless otherwise indicated, information in this prospectus concerning economic conditions, our industry,

forward-looking statements by words such as "anticipate," "believe," "continue," "could,"

forward-looking statements by words such as "anticipate," "believe," "continue," "could," "design," "estimate," "expect," "intend," "may," "plan," "potentially," "predict," "project," "should," "will" or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions, including risks described in the section titled "Risk Factors" and elsewhere in this prospectus and should not be relied upon. The

forward-looking statements in this prospectus include statements about

forward-looking statements in this prospectus include statements about: Our ability to continue as a going concern; Our ability to generate significant revenues and to become profitable; Our ability to estimate future expenses; The effect of the ongoing COVID-19 pandemic; Our ability to maintain an effective system of internal controls; Our ability to protect our intellectual property rights and to secure additional rights domestically and internationally; Our ability to successfully manage our growth domestically and internationally; Our ability to retain the services of key personnel; Our reliance on independent third-party collaborators to develop and deliver products to market; Our reliance on key management personnel and future need for highly skilled personnel; Our ability to successfully develop sales and marketing for our products; Market acceptance of pricing and performance for products we develop; 4 Our ability to generate sustainable earnings and net operating profits; Our ability to adapt to regulatory and technology changes impacting our industry; The potential for product liability claims regarding our products and the use of GMOs in our production system; Actions taken or omitted to be taken by third parties including our suppliers and competitors, as well as legislative, regulatory, judicial, and other governmental authorities; Competition in our industry; The loss of or failure to obtain any license or permit necessary or desirable in the operation of our business; The availability of additional capital to support development; Our production system is based upon living transgenic organisms; and Certain other risks and uncertainties set forth elsewhere in this prospectus under the section titled "Risk Factors". These risks are not exhaustive. Other sections of this prospectus may include additional factors that could harm our business and financial performance. Moreover, we operate in a very competitive

View Full Filing

View this S-1 filing on SEC EDGAR